Targeting the lymphatics using dendritic polymers (dendrimers)

被引:95
作者
Kaminskas, Lisa M. [1 ]
Porter, Christopher J. H. [1 ]
机构
[1] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia
基金
澳大利亚研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Dendrimer; Lymphatic transport; Magnetic resonance imaging; Drug delivery; Lymphangiography; Pharmacokinetics; Bioavailability; Polymer; Protein; MAGNETIC RESONANCE LYMPHANGIOGRAPHY; POTENTIAL ORAL DELIVERY; MR CONTRAST AGENTS; DRUG-DELIVERY; SUBCUTANEOUS INJECTION; PAMAM DENDRIMERS; SYSTEMIC AVAILABILITY; TRANSPORT; ABSORPTION; TUMOR;
D O I
10.1016/j.addr.2011.05.016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dendrimers are unique biomaterials that are constructed by the stepwise addition of layers (generations) of polymer around a central core. They can be constructed with a range of molecular weights and have a polyfunctional surface that facilitates the attachment of drugs and pharmacokinetic modifiers such PEG or targeting moieties. These properties have led to considerable interest in the development of dendrimers for a range of biomedical applications. After subcutaneous administration, larger dendrimers in particular (>8 nm), preferentially drain from the injection site into the peripheral lymphatic capillaries and therefore have potential as lymphatic imaging agents for magnetic resonance and optical fluorescence lymphangiography and as vectors for drug-targeting to lymphatic sites of disease progression. In general, lymphatic targeting of dendrimers is enhanced by increasing size although ultimately larger constructs may be incompletely absorbed from the injection site. Increasing hydrophilicity and reducing surface charge enhances drainage from subcutaneous injection sites, but the reverse is true of uptake into lymph nodes where charge and hydrophobicity promote retention. Larger hydrophilic dendrimers are also capable of extravasation from the systemic circulation, absorption into the lymphatic system and recirculation into the blood. Lymphatic recirculation may therefore be a characteristic of PEGylated dendrimers with long systemic circulation times. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:890 / 900
页数:11
相关论文
共 93 条
[1]   Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature [J].
Backer, MV ;
Gaynutdinov, TI ;
Patel, V ;
Bandyopadhyaya, AK ;
Thirumamagal, BTS ;
Tjarks, W ;
Barth, RF ;
Claffey, K ;
Backer, JM .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) :1423-1429
[2]   Synthesis and Evaluation of Pegylated Dendrimeric Nanocarrier for Pulmonary Delivery of Low Molecular Weight Heparin [J].
Bai, Shuhua ;
Ahsan, Fakhrul .
PHARMACEUTICAL RESEARCH, 2009, 26 (03) :539-548
[3]   Lymphatic spread of cervical cancer: An anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy [J].
BenedettiPanici, P ;
Maneschi, F ;
Scambia, G ;
Greggi, S ;
Cutillo, G ;
DAndrea, G ;
Rabitti, C ;
Coronetta, F ;
Capelli, A ;
Mancuso, S .
GYNECOLOGIC ONCOLOGY, 1996, 62 (01) :19-24
[4]   A PEGylated dendritic nanoparticulate carrier of fluorouracil [J].
Bhadra, D ;
Bhadra, S ;
Jain, S ;
Jain, NK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 257 (1-2) :111-124
[5]  
BOCCI V, 1988, J BIOL RESP MODIF, V7, P390
[6]  
Boyd Michael, 2004, Journal of Pharmacological and Toxicological Methods, V49, P115, DOI 10.1016/j.vascn.2003.11.004
[7]   Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model [J].
Charman, SA ;
McLennan, DN ;
Edwards, GA ;
Porter, CJH .
PHARMACEUTICAL RESEARCH, 2001, 18 (11) :1620-1626
[8]  
Charman SA, 2000, J PHARM SCI, V89, P168, DOI 10.1002/(SICI)1520-6017(200002)89:2<168::AID-JPS4>3.3.CO
[9]  
2-H
[10]   Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin [J].
Chauhan, AS ;
Sridevi, S ;
Chalasani, KB ;
Jain, AK ;
Jain, SK ;
Jain, NK ;
Diwan, PV .
JOURNAL OF CONTROLLED RELEASE, 2003, 90 (03) :335-343